[en] Data are scarce on patients infected with hepatitis C virus of genotype 5, due to the low prevalence of this genotype around the world. To better define the characteristics of these patients, we reviewed the files of 16 genotype 5 patients. Mean age was 38 +/- 14. All patients were of European origin. Most of them (75%) had been contaminated by transfusion within a short time period (between 1980 and 1991). There were no intravenous drug addicts. Seven patients received treatment. One patient did not respond to interferon (IFN) monotherapy. Of four patients treated with IFN and ribavirin, three became sustained viral responders. Two patients treated with pegylated IFN and ribavirin became sustained viral responders. In our region, genotype 5 patients seem to have been contaminated within a relatively short time period. Treatment with IFN or pegylated IFN and ribavirin gave a high rate (83%) of sustained viral responses.
Disciplines :
Gastroenterology & hepatology Hematology
Author, co-author :
Delwaide, Jean ; Université de Liège - ULiège > Gastro-Entérologie-Hépatologie
Gerard, Christiane ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie biologique et immuno hématologie
Reenaers, Catherine ; Université de Liège - ULiège > Département des sciences cliniques > Rhumatologie
Vaira, Dolorès ; Centre Hospitalier Universitaire de Liège - CHU > Immuno-hématologie
Bastens, B.
Bataille, Christian ; Université de Liège - ULiège > Département des sciences cliniques
Serwir, Brigitte ; Centre Hospitalier Universitaire de Liège - CHU > Administration des patients - Encodage
Maes, B.
Belaiche, Jacques ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Groupe Liegeois d'études des Virus Hepatotropes
Language :
English
Title :
Hepatitis C virus genotype 5 in southern Belgium: Epidemiological characteristics and response to therapy
Zein N: Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 13(2):223-235, 2000
Davidson F, Simmonds P, Ferguson J, Jarvis L, Dow B, Follet E, Seed C, Krusius T, Lin C, Medgyesi G, Kiyokawa H, Olim G, Duraisamy G, Cypers T, Saeed A, Teo D, Conradie J, Kew M, Lin M, Nuchaprayoon C, Ndimbie O, Yap P : Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5′ non-coding region. J Gen Virol 76:1197-1204, 1995
Simmonds P: Variability of hepatitis C virus. Hepatology 21(2):570-581, 1995
Blatt L, Mutchnick M, Tong M, Klion F, Lebovics E, Freilich B, Bach N, Smith C, Herrera J, Tobias H, Conrad A, Schmid P, Mc Hutchison J: Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepatol 7:196-202, 2000
Ross R, Viazov S, Renzing-Kohler K, Roggendorf M: Changes in the epidemiology of hepatitis C infection in Germany: shift in the predominance of hepatitis C subtypes. J Med Virol 60:122-125, 2000
Levi J, Takaoka D, Garrini R, Fachini R, Focaccia R, De Bortholi Santos E, Mitre H, De Mendonça J, De Paula Cavalheiro N, Barone A, Wendel S: Three cases of infection with hepatitis C virus genotypes 5 among Brazilian hepatitis patients. J Clin Microbiol 40:2645-2647, 2002
Shobokshi O, Serebour F, Skakni L, Al-Saffy H, Ahdal M: Hepatitis C genotypes and subtypes in Saudi Arabia. J Med Virol 58:44-48, 1999
Legrand-Abravanel F, Sandrès-Sauné K, Barange K, Alric L, Moreau J, Desmorat P, Vinel J, Izopet J: Hepatitis C virus genotype 5: epidemiological characteristics and sensitivity to combination therapy with interferon-α plus ribavirin. J Infect Dis 189:1397-1400, 2004
Murphy DG, Willems B, Vincelette J, Bernier L, Cote J, Delage G: Biological and clinicopathological features associated with hepatitis C virus type 5 infections. J Hepatol 24:109-113, 1996
Jover R, Pérez-Serra J, De Vera F, Alamo J, Munoz C, Yago C, Martinez-Ramirez R, Vidal J: Infection by genotype 5a of HCV in a district of Southeast Spain. Am J Gastroenterol 96:3042-3043, 2001
Henquell C, Cartau C, Abergel A, Laurichesse H, Regagnon C, De Champs C, Bailly JL, Peigue-Lafeuille H: High prevalence of hepatitis C virus type 5 in Central France evidenced by a prospective study from 1996 to 2002. J Clin Microbiol 42(7):3030-3035, 2004
Chamberlain R, Adams N, Taylor L, Simmonds P, Elliott R: The complete coding sequence of hepatitis C virus genotype 5a, the predominant genotype in South Africa. Biochem Biophys Res Commun 236(1):44-49, 1997
Strader D, Wright T, Thomas D, Seeff L: Diagnosis, management, and treatment of hepatitis C. AASLD practice guideline. Hepatology 39(4):1147-1171, 2004
Bedossa P, Poynard T: An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24:289-293, 1996
Imbert-Bismut F, Ratziu v, Pieroni L, Charlotte F, Benhamou Y, Poynard T: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357:1069-1075, 2001
Bukh J, Apgar C, Engle R, Govindarajan S, Hegerich P, Tellier R, Wong D, Elkins R, Kew M: Experimental infection of chimpanzees with hepatitis C virus of genotype 5a: genetic analysis of the virus and generation of a standardized challenge pool. J Infect Dis 178(4):1193-1197, 1998
Kedda M, Kew M, Coppi A: Hepatocarcinogenic potential of genotype 5 of hepatitis C virus. Trop. Gastroenterol 18:153-155, 1997
Bonny C, Roche C, Randl K, Ughetto S, Henquell C, Martineau N, Fontaine H, Pol S, Lafeuille H, Bommelaer G, Abergel A: Treatment of interferon- naïve patients with HCV genotype 5 wiith interferon (or peginterferon) plus ribavirin results in a very high sustained viral response. Hepatology 38(4):A75, 2003
